F2RL1 and chondrosarcoma: This includes strategies for PAR-2 modulation in chondrosarcoma and CRC therapeutics, advancing clinical potential through PK-PD modeling and GMP-grade formulation development, employing advanced proteomics and AI-driven approaches for target identification and binding characterization, and addressing the current paucity of dedicated clinical trials.